Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY: Adjunctive Pimavanserin in Major Depressive Disorder
NCT03018340Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pimavanserin in major depressive disorder (MDD), sponsored by Acadia Pharmaceuticals. Started Dec 2016; status: completed.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03018340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018340.